home / stock / cnta / cnta quote
Last: | $8.74 |
---|---|
Change Percent: | 1.05% |
Open: | $8.49 |
Close: | $8.74 |
High: | $8.74 |
Low: | $8.46 |
Volume: | 139,690 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.74 | $8.49 | $8.74 | $8.74 | $8.46 | 139,690 | 07-05-2024 |
$8.58 | $8.8 | $8.58 | $8.81 | $8.5 | 110,226 | 07-04-2024 |
$8.58 | $8.8 | $8.58 | $8.81 | $8.5 | 110,226 | 07-03-2024 |
$8.77 | $8.7 | $8.77 | $9.04 | $8.7 | 217,972 | 07-02-2024 |
$8.8 | $9 | $8.8 | $9.055 | $8.6 | 202,816 | 07-01-2024 |
$9.03 | $8.92 | $9.03 | $9.03 | $8.75 | 500,351 | 06-28-2024 |
$8.98 | $8.96 | $8.98 | $9.025 | $8.85 | 245,937 | 06-27-2024 |
$8.99 | $8.83 | $8.99 | $9 | $8.76 | 185,144 | 06-26-2024 |
$8.89 | $8.84 | $8.89 | $9.09 | $8.75 | 192,537 | 06-25-2024 |
$8.89 | $9.14 | $8.89 | $9.3 | $8.75 | 106,720 | 06-24-2024 |
$9.1 | $9 | $9.1 | $9.62 | $8.75 | 482,399 | 06-21-2024 |
$8.86 | $8.5 | $8.86 | $8.94 | $8.5 | 351,029 | 06-20-2024 |
$8.515 | $9.56 | $8.515 | $9.75 | $8.5 | 489,425 | 06-19-2024 |
$8.515 | $9.56 | $8.515 | $9.75 | $8.5 | 489,425 | 06-18-2024 |
$9.53 | $10.19 | $9.53 | $10.2 | $9.1812 | 374,121 | 06-17-2024 |
$10.18 | $9.84 | $10.18 | $10.24 | $9.83 | 191,175 | 06-14-2024 |
$9.93 | $9.76 | $9.93 | $10.1 | $9.75 | 322,832 | 06-13-2024 |
$9.7 | $9.6 | $9.7 | $10.02 | $9.37 | 299,073 | 06-12-2024 |
$9.33 | $9.29 | $9.33 | $9.527 | $9.23 | 112,304 | 06-11-2024 |
$9.08 | $8.75 | $9.08 | $9.23 | $8.71 | 152,013 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Centessa Pharmaceuticals plc Company Name:
CNTA Stock Symbol:
NASDAQ Market:
Centessa Pharmaceuticals plc Website:
2024-06-21 11:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for CNTA on June 21, 2024 09:17AM ET. The previous analyst recommendation was Equal-Weight. CNTA was trading at $9.28 at issue of the analyst recommendation. The overall analyst consensus : ...
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Fi...
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and sel...